MYELODYSPLASTIC SYNDROME (MDS)
Clinical trials for MYELODYSPLASTIC SYNDROME (MDS) explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC SYNDROME (MDS) trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC SYNDROME (MDS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo tested for Tough-to-Treat blood cancers
Disease control CompletedThis early-stage study tested a new drug called PRT2527, both by itself and combined with other cancer drugs, in people with advanced blood cancers that had returned or stopped responding to standard treatments. The main goals were to find a safe dose and see if the treatments sh…
Matched conditions: MYELODYSPLASTIC SYNDROME (MDS)
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New pill targets tough blood cancers in major trial
Disease control CompletedThis study tested a new oral drug called pelabresib for people with advanced blood cancers like myelofibrosis. The first part aimed to find a safe dose. The second part tested if pelabresib, given alone or with another drug (ruxolitinib), could shrink enlarged spleens, reduce the…
Matched conditions: MYELODYSPLASTIC SYNDROME (MDS)
Phase: PHASE1, PHASE2 • Sponsor: Constellation Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
One donor, two transplants: experimental procedure aims to cure blood cancer and fix kidneys
Disease control CompletedThis pilot study tested a combined transplant from a partially matched family donor. It aimed to treat patients who had both a serious blood disorder (like leukemia) and advanced kidney disease at the same time. The goal was to cure the blood disorder and restore kidney function …
Matched conditions: MYELODYSPLASTIC SYNDROME (MDS)
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
First human test of new blood disorder drug shows early safety profile
Knowledge-focused CompletedThis was an early-stage study to check the safety and see how the body handles a new drug called LP-001. It involved 68 healthy volunteers and tested single and multiple doses. The main goal was to see what side effects might occur and to measure how long the drug stays in the bl…
Matched conditions: MYELODYSPLASTIC SYNDROME (MDS)
Phase: PHASE1 • Sponsor: Longbio Pharma • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:16 UTC
-
A multicenter, randomized, phase III registration trial of transplantation of NiCord®, ex vivo expanded, UCB-derived, stem and progenitor cells, vs. unmanipulated UCB for patients with hematological malignancies
CompletedThis study is an open-label, controlled, multicenter, international, Phase III, randomized study of transplantation of NiCord® versus transplantation of one or two unmanipulated, unrelated cord blood units in patients with acute lymphoblastic leukemia or acute myeloid leukemia, m…
Matched conditions: MYELODYSPLASTIC SYNDROME (MDS)
Phase: PHASE3 • Sponsor: Gamida Cell ltd
Last updated Mar 02, 2026 15:25 UTC